COG4-CDG

COG4-CDG (also known as congenital disorder of glycosylation type IIj) is an extremely rare autosomal recessive disorder caused by pathogenic variants in the COG4 gene, which encodes subunit 4 of the conserved oligomeric Golgi (COG) complex. The COG complex plays a critical role in the proper functioning of the Golgi apparatus, which is essential for the glycosylation of proteins and lipids. Defects in COG4 lead to impaired Golgi-mediated glycosylation, resulting in a multisystem disorder classified among the congenital disorders of glycosylation (CDG) type II. Clinical features of COG4-CDG are variable but typically present in infancy or early childhood. Affected individuals may exhibit neurological involvement including developmental delay, intellectual disability, seizures, and microcephaly. Other commonly reported features include hypotonia, failure to thrive, hepatic dysfunction with elevated liver transaminases, and recurrent infections. Skeletal abnormalities, short stature, and dysmorphic facial features have also been described in some patients. Laboratory findings characteristically show abnormal isoelectric focusing of serum transferrin consistent with a type 2 pattern, reflecting defective Golgi-based glycosylation. There is currently no specific or curative treatment for COG4-CDG. Management is supportive and symptomatic, involving a multidisciplinary team that may include neurologists, gastroenterologists, geneticists, and rehabilitation specialists. Interventions are tailored to individual symptoms and may include nutritional support, anti-epileptic medications for seizure management, and physical and occupational therapy to optimize developmental outcomes. Given the rarity of this condition, only a small number of patients have been reported in the medical literature, and the full clinical spectrum continues to be defined as additional cases are identified.

Common questions about COG4-CDG